登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
ClinicalTrials.gov 上登记的一项肺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT05487391,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Stage II-IIIB according to the 8th edition of the American Joint Committee on Cancer (AJCC) , and had received radical surgical resection (R0) treatment.
入选标准第 3 条
Participants were enrolled to receive adjuvant therapy within 10 weeks after surgery (≤70 days) and had to recover sufficiently from surgery.
入选标准第 4 条
Subjects (including women and men) agreed to use effective contraception from the time of signing the informed consent to 180 days after the last use of the study drug.
入选标准第 7 条
Currently participating in and receiving study treatment or participating in an investigational drug study and receiving study treatment or using an investigational device within 4 weeks prior to the first dose of study treatment.
排除标准第 1 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 6 条
Human immunodeficiency virus (HIV) antibody positive; Treponema pallidum antibody positive.
排除标准第 6 条
Other malignancies occurred within 5 years prior to study enrollment. (Except: Bowen's disease; cured basal cell or squamous cell skin cancer; prostate cancer with a Gleason score of 6; treated cervical carcinoma in situ.)
排除标准第 9 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;影像与可测量病灶;怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05487391,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Subjects voluntarily participated, signed an informed consent form (ICF), and were able to follow the study procedures. Histopathologically confirmed squamous or non-squamous non-small cell lung cancer Stage II-IIIB according to the 8th edition of the American Joint Committee on Cancer (AJCC) , and had received radical surgical resection (R0) treatment. Participants were enrolled to receive adjuvant therapy within 10 weeks after surgery (≤70 days) and had to recover sufficiently from surgery. Non-squamous NSCLC subjects without EGFR-sensitizing mutation or ALK fusion gene. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Subjects (including women and men) agreed to use effective contraception from the time of signing the informed consent to 180 days after the last use of the study drug.排除标准:Exclusion Criteria:
Currently participating in and receiving study treatment or participating in an investigational drug study and receiving study treatment or using an investigational device within 4 weeks prior to the first dose of study treatment. Previous treatment with neoadjuvant/adjuvant chemotherapy or immune checkpoint inhibitor therapy. Cardiovascular and cerebrovascular diseases with clinical significance. Gastrointestinal disease of clinical significance. Clinically significant lung damage. Human immunodeficiency virus (HIV) antibody positive; Treponema pallidum antibody positive. Active uncontrolled hepatitis B or active hepatitis C. Administer a live vaccine within 30 days prior to the first dose of study treatment. Other malignancies occurred within 5 years prior to study enrollment. (Except: Bowen's disease; cured basal cell or squamous cell skin cancer; prostate cancer with a Gleason score of 6; treated cervical carcinoma in situ.) Previously allergic to macromolecular protein preparations, or to any component of QL1706 and other investigational drugs; history of severe allergy to chemotherapy drugs (pemetrexed, vinorelbine, paclitaxel, cisplatin, carboplatin) or their preventive drugs, etc. History of psychotropic substance abuse, alcohol or drug abuse; prior history of clear neurological or psychiatric disorders, including epilepsy or dementia.
引自 ClinicalTrials.gov, NCT05487391, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05487391,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。